BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Andamertinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Andamertinib\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07336732-2208@assetmemo.bio
DTSTAMP:20261121T005655Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Andamertinib: Phase 2 readout est. (NCT07336732)
DESCRIPTION:Andamertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: An
 damertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-d
 oublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutatio
 ns\nEstimated primary completion: November 2026. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/andamertinib#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07336732
URL:https://assetmemo.bio/drug/andamertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06343064-2208@assetmemo.bio
DTSTAMP:20261121T005655Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Andamertinib: Phase 1/2 readout est. (NCT06343064)
DESCRIPTION:Andamertinib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: 
 Vebreltinib Plus PLB1004 in EGFR-mutated\, Advanced NSCLC With MET Amplifi
 cation or MET Overexpression Following EGFR-TKI\nEstimated primary complet
 ion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/andamertinib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06343064
URL:https://assetmemo.bio/drug/andamertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06970782-2208@assetmemo.bio
DTSTAMP:20261121T005655Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Andamertinib: Phase 3 readout est. (NCT06970782)
DESCRIPTION:Andamertinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Ve
 breltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patie
 nts With EGFRm\, MET+\, Locally Advanced or Metastatic NSCLC Following EGF
 R-TKI Failure\nEstimated primary completion: 31 December 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/andamertinib#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06970782
URL:https://assetmemo.bio/drug/andamertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06046495-2208@assetmemo.bio
DTSTAMP:20261121T005655Z
DTSTART;VALUE=DATE:20280209
DTEND;VALUE=DATE:20280210
SUMMARY:Andamertinib: Phase 1 readout est. (NCT06046495)
DESCRIPTION:Andamertinib\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A 
 Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer\nEs
 timated primary completion: 9 February 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/andamertinib#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06046495
URL:https://assetmemo.bio/drug/andamertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07063329-2208@assetmemo.bio
DTSTAMP:20261121T005655Z
DTSTART;VALUE=DATE:20280308
DTEND;VALUE=DATE:20280309
SUMMARY:Andamertinib: Phase 1/2 readout est. (NCT07063329)
DESCRIPTION:Andamertinib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: 
 Phase I/II Study of PLB1004 Combined With Platinum-based Doublet Chemother
 apy in Patients With EGFR Mutation-positive\nEstimated primary completion:
  8 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/andame
 rtinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07063329
URL:https://assetmemo.bio/drug/andamertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06281964-2208@assetmemo.bio
DTSTAMP:20261121T005655Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Andamertinib: Phase 3 readout est. (NCT06281964)
DESCRIPTION:Andamertinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Ef
 ficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCL
 C Harboring EGFR Exon 20 Insertion.\nEstimated primary completion: 30 June
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/andamertinib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06281
 964
URL:https://assetmemo.bio/drug/andamertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07780578-2208@assetmemo.bio
DTSTAMP:20261121T005655Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Andamertinib: Phase 2 readout est. (NCT07780578)
DESCRIPTION:Andamertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Th
 e Study Of Andamertinib Plus Anlotinib In Patients With Locally Advanced o
 r Metastatic Non-Small Cell Lung Cancer\nEstimated primary completion: 30 
 September 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/andam
 ertinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07780578
URL:https://assetmemo.bio/drug/andamertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07285148-2208@assetmemo.bio
DTSTAMP:20261121T005655Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Andamertinib: Phase 1/2 readout est. (NCT07285148)
DESCRIPTION:Andamertinib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: 
 A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Ce
 ll Lung Cancer\nEstimated primary completion: December 2029. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/andamertinib#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07285148
URL:https://assetmemo.bio/drug/andamertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
